Fuglsang G, Pedersen S
Department of Pediatrics, Aalborg Hospital, Denmark.
Allergy. 1988 Jul;43(5):348-52. doi: 10.1111/j.1398-9995.1988.tb00428.x.
In a controlled, open cross-over study 15 asthmatic children received increasing doses of terbutaline (0.125 mg + 0.125 mg + 0.25 mg + 0.5 mg + 0.1 mg) delivered by a pressurized aerosol alone or with a tube spacer or a nebuhaler attached. At no time was there any significant difference in measured FEV1 or percent increase in FEV1 between the three inhalers. However, when eight patients with bronchodilation greater than 50% on all tests days were studied separately, a significantly greater improvement in FEV1 was seen after the first three inhalations of terbutaline when a nebuhaler or a tube spacer was used compared with the response after the pressurized aerosol (P less than 0.05) Bronchodilation measurements did not differ after use of the two spacers. There was no statistically significant difference in side effects between the three inhalers, but there was a trend towards a higher occurrence of side effects when the pressurized aerosol was used alone.
在一项对照开放交叉研究中,15名哮喘儿童接受了递增剂量的特布他林(0.125毫克 + 0.125毫克 + 0.25毫克 + 0.5毫克 + 1毫克),分别通过单独使用压力定量气雾剂、搭配储雾罐或雾化器给药。在任何时间点,三种吸入装置在测量的第一秒用力呼气容积(FEV1)或FEV1增加百分比方面均无显著差异。然而,当对在所有测试日支气管扩张大于50%的8名患者进行单独研究时,与使用压力定量气雾剂后的反应相比,使用雾化器或储雾罐时,在前三次吸入特布他林后FEV1有显著更大的改善(P小于0.05)。使用两种储雾罐后支气管扩张测量结果无差异。三种吸入装置在副作用方面无统计学显著差异,但单独使用压力定量气雾剂时副作用有更高发生率的趋势。